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1. Introduction
In the United Kingdom (UK) there were approximately 46,403 new cases of lung cancer 
diagnosed in 2014. There were a reported 35,895 deaths directly related to the onset of 
lung cancer in the UK in 2014. Although there have been some significant improvements 
in the prognosis of other cancers in recent years, lung cancer is still associated with poor 
survival due to it being diagnosed predominantly at a later stage. The detection of lung 
cancer at an earlier stage (I-II) will usually indicate a better prognosis than those 
diagnosed with late stage lung cancer (III-IV). Primarily lung cancer is more prevalent in 
smokers; however it is not exclusive to this population group and is similarly prevalent in 
ex-smokers or those exposed to second hand smoke. [1] Currently there are no approved 
national screening programmes for lung cancer in the UK. The early diagnosis of lung 
cancer is difficult as significant symptoms do not present until a patient has progressed 
into a late stage of the disease. Therefore the early diagnosis of the disease through an 
approved national screening programme would be associated with early detection and 
prolonged survival. 
2. Purpose
The aim of this review is to critically evaluate current literature looking at the use of low dose 
computed tomography (LDCT) in a lung cancer screening programme in the UK. To do this the 
primary focus of this literature review was to: 
1) Critically appraise appropriately selected randomised control trials (RCT) that explore the use of 
LDCT as a diagnostic tool in a potential lung cancer screening programme. 
2) Explore and highlight the potential advantages associated with a lung cancer screening 
programme; including the potential for less invasive treatments being utilised and the potential 
reductions in mortality.
3) Address the potential disadvantages to implementing a lung cancer screening programme in the 
UK.
Author & Date Title & Country of Origin
Pedersen et al, 
2009. [2]
‘The Danish Randomised Lung Cancer CT Screening Trial – Overall Design 
and Results of the Prevalence Round.’ (DLCST) Denmark
Van Klaveren et al, 
2009. [3]
‘Management of lung nodules detected by Volume CT scanning.’ (NELSON) 
Belgium/ Netherlands
Aberle et al, 2011. [4] ‘The National Lung Screening Trial: overview and study design.’ (NLST) USA
Becker et al, 2012 [5] ‘Randomized study on the early detection of lung cancer with MSCT in 
Germany: study design and results of the first screening round.’ (LUSI) 
Germany
Field et al, 2016. [6] ‘UK Lung cancer RCT pilot screening trial: baseline findings from the 
screening arm provide evidence for the potential implementation of lung 
cancer screening.’ (UKLS) United Kingdom
Figure 1: Papers selected after application of inclusion and exclusion criteria.
Figure 2: CT slice identifying detection of lung nodule (yellow 
arrow) derived from Ritchie et al (2016).[7]
Figure 3: Lung nodule classification, interpretation and pathway derived from the 
UKLS trial (2016). [6]
3. Method
A literature search was conducted to identify articles which reported on the effect of LDCT in 
the screening of lung cancer. Papers were selected based on strict inclusion and exclusion 
criteria. The CASP tool was used to critically appraise and evaluate each paper. Through 
analysis of the papers further appropriate papers were identified by snowballing. The 
methods and results of the selected papers were critically reviewed. From this literature 
search, 5 relevant papers were selected based on the search criteria set in this review. (Fig 1)
The critical analysis of these papers yielded consistent themes that enabled discussion for all 
5 papers.
3.1. RCT: Method
Each RCT aimed to assess LDCT as a diagnostic tool for potential lung cancer screening 
programme with an overall endpoint of mortality reduction. The selection of participants 
followed a similar process throughout each trial; they all utilised a voluntary process, were 
based on risk stratification models and were all randomised into a screening and control arm. 
The method of scanning with LDCT was with initial base line scan followed by subsequent 
scans at varied intervals in each trial. The method of assessment of lung nodules (Fig 2) was 
also varied in each trial as they were based on trust specific protocols. (Fig 3)
Low dose LDCT Screen
Nodules (single or multiple) Advanced Cancer
CATEGORY 1 (benign 
nodule or <3mm 
diameter or 15mm3 
volume)
CATEGORY 2 (solid nodule 
3mm – 4.9mm diameter 
or 15mm3 – 49mm3 
volume)
CATEGORY 3 (solid nodule 
or 5mm- 9.9mm diameter 
or 50mm3 – 500mm3 
volume)
CATEGORY 4 (solid nodule 
or >10mm diameter or 
>500m3 volume)
Follow CT in 1 year
Growth VDT <400 days 
or new solid component 
of non-solid nodule
NO YES
STOP
Follow CT in 3 months
NO YES
Growth VDT <400 days 
or new solid component 
of non-solid nodule
Follow up CT in 9 months
VDT <400 days
NO YES
MDT ASSESSMENT
4. Key Findings
• The NLST found an overall 20% reduction in lung cancer mortality using LDCT versus conventional 
chest x-ray. 
• The NELSON found evidence for optimal screening interval time at 2.5 years which reduces the 
number of missed cancers. 
• The analysis of cancerous nodules using volume (mm3) rather than diameter (mm) increased 
sensitivity and the detection of early stage (I-II) lung cancer was significantly higher than late stage 
(III-IV) lung cancer in all the trials.
• The NLST data aside; other trials in this review can only speculate on the long term effects of LDCT 
screening on mortality. 
• LDCT has high sensitivity but it is not specific for malignancy and therefore may result in false 
positive results. 
• Evidence of inter-observer variability in the method of analysis of lung nodules across all trials. 
• DLCST, LUSI and UKLS trials had low participant uptake; thus compromising the validity of the 
results. 
• There was not a significant representation of lower socioeconomic  groups in all the trials. 
5. Conclusion
The implementation of a screening programme has the potential to reduce lung cancer related mortality in the UK. The detection of early stage (I-II) lung cancer is higher than late stage (III-IV) lung 
cancer due to the high sensitivity of LDCT. This will result in the use of less invasive treatments, thus improving patient QoL. However, lower socio-economic location with high smoking prevalence is 
associated with poorer uptake in the UKLS suggesting a false representation of the target population for screening. An inconsistent review system across the screening trials is open to observer variability 
and the potential negative impact of false-positive results and overdiagnosis are also evident. These barriers must be addressed to justify a lung cancer screening programme in the UK.[8, 9]
[9]
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